Previously submitted to: Interactive Journal of Medical Research (no longer under consideration since Jun 29, 2023)
Date Submitted: Jul 20, 2022
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
A study of clinical characteristics and risk factors of mortality associated with tigecycline
ABSTRACT
Background:
Tigecycline has a broad spectrum of antimicrobial activity and become more widely used. However, in 2010, the FDA warned that tigecycline was associated with an increased risk of death. The risk factors of tigecycline-associated mortality are still controversial.
Objective:
The objective of this study was to explore the related factors of mortality associated with tigecycline in a tertiary university hospital and to establish the risk assessment criteria for tigecycline associated mortality
Methods:
In a observational retrospective study, we enrolled 240 patients who had been treated for at least 3 days with tigecycline between January 2020 and December 2020. We compared the clinical characteristics of patients who died after tigecycline therapy (79 in the non-survivor group) with those who survived within 28 days after tigecycline therapy (161 in the survivor group) during the same hospitalization. We used a logistic regression model to find risk factors of tigecycline associated mortality.
Results:
In total, 240 patients were included in the analysis, 79 patients eventually died after tigecycline treatment. The ages of the non-survivor group and survivor group were 78.3±13.9 and 68.0±11.2 years old (p = 0.022), treatment duration were 11±8.5 and 7±6.6 day (p = 0.017), and the APACHE II score were 14.8±4.0 and 9.5±2.7 (p = 0.025). The serum creatinine (SCr) was significant difference before and after treated with tigecycline only in the non-survivor group and no significant difference in the survivor group. The proportion of the kidney failure events and change in creatinine value were greater in the non-survivor group after treated with tigecycline than in the survivor group (p < 0.001).. In the multivariate analysis, age(p=0.019), ΔCre(p＜0.001) , SCr(p=0.038), APACHE II score (p=0.031) were independently associated with mortality. An age of ≥79 years, ΔCre(μmol/L)≥36, SCr≥112 and APACHE II score≥12.7 were selected as the cutoff points for predicting tigecycline associated mortality. The distribution of non-survivors at different ranges of creatinine change showed higher percentages of mortality in patients with high ΔCre after tigecycline treatment.
Conclusions:
This study identifies the risk factors for tigecycline associated mortality, and draws attention to the fact that there is an increased mortality risk in patients treated with tigecycline . The risk assessment criteria can be helpful to identify patients with high risk of tigecycline associated mortality. Clinical Trial: no trial
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.